Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors

Add time:08/30/2019    Source:sciencedirect.com

Taking the pyrrolopyrimidine derived IGF-1R inhibitor NVP-AEW541 as the starting point, the benzyl ether back-pocket binding moiety was replaced with a series of 2-cyclic ether methyl ethers leading to the identification of novel achiral [2.2.1]-bicyclic ether methyl ether containing analogues with improved IGF-1R activities and kinase selectivities. Further exploration of the series, including a fluorine scan of the 5-phenyl substituent, and optimisation of the sugar-pocket binding moiety identified compound 33 containing (S)-2-tetrahydrofuran methyl ether 6-fluorophenyl ether back-pocket, and cis-N-Ac-Pip sugar-pocket binding groups. Compound 33 showed improved selectivity and pharmacokinetics compared to NVP-AEW541, and produced comparable in vivo efficacy to linsitinib in inhibiting the growth of an IGF-1R dependent tumour xenograft model in the mouse.

We also recommend Trading Suppliers and Manufacturers of L-TYROSINE, O-(4-HYDROXYPHENYL)-3,5-DIIODO-, METHYL ESTER, HYDROCHLORIDE (cas 111149-73-6). Pls Click Website Link as below: cas 111149-73-6 suppliers

Prev:Synthesis of d- and l-tyrosine-chlorambucil analogs active against breast cancer cell lines
Next:ArticleMolecular mechanism underlying the subtype-selectivity of competitive inhibitor NF110 (cas 111150-22-2) and its distinct potencies in human and rat P2X3 receptors)